Chronic Spontaneous Urticaria Treatment Market Size Share Industry 2023-2030

Chronic Spontaneous Urticaria Treatment Market Report Size

Global Chronic Spontaneous Urticaria Treatment Market Expected to Reach US$ YY Million by 2030 with a High CAGR Market Insights and Dynamics Unveiled

The global chronic spontaneous urticaria treatment market, also known as chronic idiopathic urticaria, demonstrated remarkable growth, reaching US$ YY million in 2022. Projections indicate that the market is poised to further surge, reaching a remarkable US$ YY million by 2030. This significant growth is attributed to a robust compound annual growth rate (CAGR) forecasted during the period spanning from 2023 to 2030.

Chronic spontaneous urticaria is characterized by the persistent presence of hives for a duration exceeding six weeks, often accompanied by angioedema in about 40 percent of patients. The standard management of Chronic Spontaneous Urticaria (CSU) primarily entails the use of second-generation H1 antihistamines, frequently administered at higher doses, often in conjunction with H2 antihistamines and leukotriene modifiers. In severe cases, short courses of systemic glucocorticoids may be required.

While there is no known cure for CSU, antihistamines play a crucial role in relieving itching and preventing allergic reactions. Monthly injections of omalizumab (Xolair) are known to effectively block the body's production of immunoglobin E (IgE). Corticosteroids such as prednisone (Deltasone, Rayos) are used to manage symptoms that do not respond to allergy medicines. Cyclosporine immunosuppressant has proven highly effective in treating severe chronic hives. Several other drugs are also employed to provide symptomatic relief for chronic spontaneous urticaria.

Market Scope and Metrics:

Market Size: 2021-2030

Market Estimation Forecast Period: 2023-2030

Revenue Units: Value (US$ Mn)

Segments Covered: Treatment Type, Route of Administration, and Distribution Channel

Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa

Largest Region: North America

Fastest Growing Region: Asia-Pacific

Report Insights Covered: Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other Key Insights.

To know more insights Download Sample

Chronic Spontaneous Urticaria Treatment Market Dynamics

Drivers:

The chronic spontaneous urticaria treatment market is driven by various factors, including:

Increasing Demand for Novel Drugs: The rising demand for novel drugs for the treatment of chronic spontaneous urticaria is expected to dominate the market. These innovative drugs aim to address unmet needs by providing alternative or complementary solutions for enhanced disease management. Regulatory approvals further instill patient trust in the development of novel drugs.

For example, on March 7, 2023, Regeneron Pharmaceuticals, Inc. and Sanofi announced the acceptance of their supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) by the U.S. Food and Drug Administration (FDA). Dupixent is intended to treat chronic spontaneous urticaria (CSU) in adults and adolescents aged 12 years and older who do not respond adequately to the current standard of care, H1 antihistamine treatment.

Additionally, ongoing clinical trials are in progress to develop novel drugs that exhibit superior results in chronic spontaneous urticaria treatment.

Increasing Prevalence: The rising prevalence of chronic spontaneous urticaria, coupled with increasing FDA approvals and clinical trials, is boosting market growth. Technological advancements in treatment options also play a pivotal role.

Restraints:

Despite the market's promising growth, certain factors are expected to hinder progress, including:

Complications Associated with High-Dose Corticosteroids and Other Drugs: The use of high doses of corticosteroids and other drugs can lead to complications, impeding patient acceptance.

High Treatment Costs: The high cost of treating inflammatory myositis and the lack of superior treatment options pose challenges to market expansion.

Chronic Spontaneous Urticaria Treatment Market Segment Analysis:

The global chronic spontaneous urticaria treatment market is segmented based on treatment type, route of administration, distribution channel, and region. Among these segments, antihistamines claim a substantial market share, accounting for approximately 46.3% of the chronic spontaneous urticaria treatment market.

Antihistamines are recognized as the first-line therapeutics for the symptomatic management of chronic spontaneous urticaria. Frequently used antihistamines include cetirizine, loratadine, fexofenadine, desloratadine, levocetirizine, rupatadine, blexten, and bilastine. Notably, antihistamines such as Blexten (bilastine) have been introduced for pediatric use in patients aged 4 years and older, further fueling their adoption.

In cases where antihistamines alone do not adequately control symptoms, combining them with other medications, such as leukotriene receptor antagonists, corticosteroids, or immunosuppressants, is considered for more effective disease management.

Chronic Spontaneous Urticaria Treatment Market Geographical Share:

North America is a dominant force in the global chronic spontaneous urticaria treatment market, claiming approximately 40.3% of the market share. This region's leading position can be attributed to its concentration of major pharmaceutical and biotechnology players, substantial R&D activities, and clinical trials that result in the development of novel therapeutics and alternative treatment options.

Notable developments in North America include Celldex Therapeutics, Inc.'s successful completion of patient enrollment in the Phase 2 clinical study of barzolvolimab, a humanized monoclonal antibody for the treatment of chronic spontaneous urticaria.

Competitive Landscape:

The major global players in the chronic spontaneous urticaria treatment market include F. Hoffmann-La Roche Ltd, Sanofi SA, Novartis AG, Bayer AG, Dr. Reddy’s Laboratories Ltd, STL Pharma Pvt. Ltd., Regeneron Pharmaceuticals Inc., Genentech, Inc., Jubilant Cadista Pharmaceuticals Inc., and Horizon Therapeutics plc, among others.

Related Report:

Nasal Antihistamines Market

Adrenocortical Hormones API Market

Intravenous Immunoglobulin Market

Intravenous Iron Drugs Market

Oral Transmucosal Drugs Market

Oral Anti Diabetes Drugs Market

About Us

DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

Contact Us

Name: Sai K

Designation: Sales & Senior Business Consultant

Email: info@datamintelligence.com

Phone: +1 877 441 4866

Website: https://www.datamintelligence.com